Proposed ranibizumab biosimilar shows promise for neovascular AMD
- Posted on: Feb 1 2021
- Leave a response
A new phase 3 equivalence study tested the safety and efficacy of the proposed ranibizumab biosimilar SB11.
Source: AAO
Posted in: Uncategorized
